These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 17121896)

  • 41. The Proteasome Inhibitor Marizomib Evokes Endoplasmic Reticulum Stress and Promotes Apoptosis in Human Glioblastoma Cells.
    Kusaczuk M; Tyszka N; Krętowski R; Cechowska-Pasko M
    Pharmaceuticals (Basel); 2024 Aug; 17(8):. PubMed ID: 39204194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolution of Natural Product Scaffolds as Potential Proteasome Inhibitors in Developing Cancer Therapeutics.
    Mir RH; Mir PA; Uppal J; Chawla A; Patel M; Bardakci F; Adnan M; Mohi-Ud-Din R
    Metabolites; 2023 Mar; 13(4):. PubMed ID: 37110167
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural Products from Actinobacteria as a Potential Source of New Therapies Against Colorectal Cancer: A Review.
    Bahrami Y; Bouk S; Kakaei E; Taheri M
    Front Pharmacol; 2022; 13():929161. PubMed ID: 35899111
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic and Cycling Hypoxia: Drivers of Cancer Chronic Inflammation through HIF-1 and NF-κB Activation: A Review of the Molecular Mechanisms.
    Korbecki J; Simińska D; Gąssowska-Dobrowolska M; Listos J; Gutowska I; Chlubek D; Baranowska-Bosiacka I
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639040
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition.
    Raninga PV; Lee A; Sinha D; Dong LF; Datta KK; Lu X; Kalita-de Croft P; Dutt M; Hill M; Pouliot N; Gowda H; Kalimutho M; Neuzil J; Khanna KK
    Theranostics; 2020; 10(12):5259-5275. PubMed ID: 32373211
    [No Abstract]   [Full Text] [Related]  

  • 46. Measuring the Overall Rate of Protein Breakdown in Cells and the Contributions of the Ubiquitin-Proteasome and Autophagy-Lysosomal Pathways.
    Sha Z; Zhao J; Goldberg AL
    Methods Mol Biol; 2018; 1844():261-276. PubMed ID: 30242715
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trial Watch: Proteasomal inhibitors for anticancer therapy.
    Obrist F; Manic G; Kroemer G; Vitale I; Galluzzi L
    Mol Cell Oncol; 2015; 2(2):e974463. PubMed ID: 27308423
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Curcumin Enhances the Effects of 5-Fluorouracil and Oxaliplatin in Inducing Gastric Cancer Cell Apoptosis Both In Vitro and In Vivo.
    Zhou X; Wang W; Li P; Zheng Z; Tu Y; Zhang Y; You T
    Oncol Res; 2016 Jan; 23(1-2):29-34. PubMed ID: 26802648
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier.
    Di K; Lloyd GK; Abraham V; MacLaren A; Burrows FJ; Desjardins A; Trikha M; Bota DA
    Neuro Oncol; 2016 Jun; 18(6):840-8. PubMed ID: 26681765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting tumor ubiquitin-proteasome pathway with polyphenols for chemosensitization.
    Shen M; Chan TH; Dou QP
    Anticancer Agents Med Chem; 2012 Oct; 12(8):891-901. PubMed ID: 22292765
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases.
    Sperling J; Schäfer T; Ziemann C; Benz-Weiber A; Kollmar O; Schilling MK; Menger MD
    Clin Exp Metastasis; 2012 Feb; 29(2):91-9. PubMed ID: 22052392
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The 26S proteasome complex: an attractive target for cancer therapy.
    Frankland-Searby S; Bhaumik SR
    Biochim Biophys Acta; 2012 Jan; 1825(1):64-76. PubMed ID: 22037302
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors.
    Miller CP; Singh MM; Rivera-Del Valle N; Manton CA; Chandra J
    J Biomed Biotechnol; 2011; 2011():514261. PubMed ID: 21765634
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proteasome inhibitors in cancer therapy.
    Crawford LJ; Walker B; Irvine AE
    J Cell Commun Signal; 2011 Jun; 5(2):101-10. PubMed ID: 21484190
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials.
    Potts BC; Albitar MX; Anderson KC; Baritaki S; Berkers C; Bonavida B; Chandra J; Chauhan D; Cusack JC; Fenical W; Ghobrial IM; Groll M; Jensen PR; Lam KS; Lloyd GK; McBride W; McConkey DJ; Miller CP; Neuteboom ST; Oki Y; Ovaa H; Pajonk F; Richardson PG; Roccaro AM; Sloss CM; Spear MA; Valashi E; Younes A; Palladino MA
    Curr Cancer Drug Targets; 2011 Mar; 11(3):254-84. PubMed ID: 21247382
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.
    Gulder TA; Moore BS
    Angew Chem Int Ed Engl; 2010 Dec; 49(49):9346-67. PubMed ID: 20927786
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
    Leguerney I; Lassau N; Koscielny S; Rodrigues M; Massard C; Rouffiac V; Benatsou B; Thalmensi J; Bawa O; Opolon P; Peronneau P; Roche A
    Invest New Drugs; 2012 Feb; 30(1):144-56. PubMed ID: 20924644
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.
    Shah MA; Power DG; Kindler HL; Holen KD; Kemeny MM; Ilson DH; Tang L; Capanu M; Wright JJ; Kelsen DP
    Invest New Drugs; 2011 Dec; 29(6):1475-81. PubMed ID: 20574790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides.
    Potts BC; Lam KS
    Mar Drugs; 2010 Mar; 8(4):835-80. PubMed ID: 20479958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.